CDK9-IN-41
Based on 1 Customer Validation
CDK9-IN-41 is a potent CDK9, EGFR, HER2, and COX-2 kinases inhibitor with IC50s of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM. COX-2-IN-18 exhibits remarkable antitumor activity against leukemia cancer cells, colon cancer cells, melanoma cells, ovarian cells and breast cells.
For research use only. We do not sell to patients.
- Purity : 98.84%
- CAS No.: 1038061-96-9
- Formula: C18H19N3O3S2
- Molecular Weight:389.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK9 192.81 nM (IC50) |
HER2 238.81 nM (IC50) |
EGFR 254.03 nM (IC50) |
COX-2 775 nM (IC50) |
In Vitro
CDK9-IN-41 (Compound 3) has antitumor activity presented as growth inhibition percentages (GI%) for 59 subpanel tumor cell lines. Leukemia (CCRF-CEM, 20%; HL-60(TB), 30%; MOLT-4, 20%; RPMI-8226, 20%; SR, 19%), NSC Lung (A549/ATCC, 20%; HOP-92, 14%; NCI-H322M, 19%; NCI-H23, 12%; NCI-H522, 24%), Colon (HCT-116, 21%; HCT-15, 12%), CNS (SF-539, 12%; SNB-19, 12%; U251, 12%), Melanoma (LOX IMVI, 23%; MALME-3 M, 25%; SK-MEL-5, 11%; UACC-62, 24%), Ovarian (OVCAR-8, 12%; A-498, 12%; RXF-393, 13%; UO-31, 35%), Prostate (PC-3, 13%), Breast (MDA-MB-231/ATCC, 29%; HS-578 T, 18%; T-47D, 15%; MDA-MB-468, 12%)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1038061-96-9
-
Appearance Solid
-
Molecular Weight 389.49
-
Formula C18H19N3O3S2
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(CCN2C(SCC)=NC3=C(C=CC=C3)C2=O)C=C1)(N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CDK9-IN-41 Related Classifications
HY-147794 Related Classifications
Powered by Bioz